Results
infection
INFECTION
Patients were recruited between 11 January 2018 and 10 December 2020. Figure Platelet function test results are described in Table Closure time (CT), serum thromboxane B2 (sTxB2) and plasma thromboxane B2 (pTxB2) at three different time points (during infection (days 1–3, T1), after intervention (day 14, T2) and without infection (day > 90, T3)) and the percentage change in relation to T1Data are presented as geometric means (95% CI) or % (95% CI). Linear mixed models were used to analyse the percentage changes between different time points. The number of measurements per time point and outcome are described. * Significant change within group; bold text: Change in the aspirin group is significantly different from the change in the control group; n.a.: not analysedClosure time (CT), serum thromboxane (sTxB2) and plasma thromboxane (pTxB2) during infection (days 1–3, T1), after intervention (day 14, T2) and without infection (day > 90, T3) in the control and aspirin treatment group. Each bar represents the geometric mean with its 95% confidence intervals. Linear mixed models were used to analyse the percentage changes between different time points. * Significant change within group; ** the change in the aspirin group is significant compared to the change in the control groupIn the intervention group, aspirin caused a prolongation of the CT of 100% (95%CI 77; 127) from T1 towards T2, which is significantly higher than the observed increase of only 12% (95%CI 1; 25) in the control group. For sTxB2, we also observed a significant effect of aspirin: The change in sTxB2 from T1 to T2 was − 95% (95%CI − 97; − 92), while in the control group, sTxB2 increased from T1 to T2 with 52% (95%CI 3; 125). The change in pTxB2 was comparable for both groups: + 42% (95%CI 13; 80) in the aspirin group and also + 42% (95%CI − 9; 123) in the control group. There were no significant differences between aspirin regimen groups (once-daily 80 mg and twice-daily 40 mg) for CT and pTxB2, but the effect of aspirin on sTxB2 decrease was slightly stronger in the once-daily aspirin regimen group compared with the twice-daily group (data not shown).In the control group as well as the aspirin group, results were not influenced by sex. There were no associations between CT, sTxB2 or pTxB2 and platelet count at baseline, or change in platelet count throughout the study period. The platelet counts at different time points in the control group and the aspirin group are provided as supplementary information (SI 1).